Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A. Heitz F, et al. Among authors: reinthaller a. Gynecol Oncol. 2019 Feb;152(2):235-242. doi: 10.1016/j.ygyno.2018.11.008. Epub 2018 Nov 20. Gynecol Oncol. 2019. PMID: 30466805 Clinical Trial.
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Floquet A, et al. Among authors: reinthaller a. Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28. Gynecol Oncol. 2015. PMID: 25434635 Clinical Trial.
Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
Ataseven B, du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, Prader S, Polterauer S, Harter P, Grimm C. Ataseven B, et al. Among authors: reinthaller a. Gynecol Oncol. 2015 Sep;138(3):560-5. doi: 10.1016/j.ygyno.2015.07.005. Epub 2015 Jul 8. Gynecol Oncol. 2015. PMID: 26163893
Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.
Kranawetter M, Ataseven B, Grimm C, Schneider S, Riss S, Alesina P, Prader S, Walz MK, Harpain F, Stift A, Heitz F, Reinthaller A, Polterauer S, Harter P, du Bois A. Kranawetter M, et al. Among authors: reinthaller a. Gynecol Oncol. 2019 Sep;154(3):577-582. doi: 10.1016/j.ygyno.2019.06.015. Epub 2019 Jun 21. Gynecol Oncol. 2019. PMID: 31235241
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Harter P, et al. Among authors: reinthaller a. Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd. Int J Gynecol Cancer. 2011. PMID: 21270612
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial.
Grimm C, Polterauer S, Helmy-Bader S, Zikan M, Cibula D, Heitz F, Harter P, Giese A, Reinthaller A, Tempfer C. Grimm C, et al. Among authors: reinthaller a. Gynecol Oncol. 2018 Apr;149(1):140-145. doi: 10.1016/j.ygyno.2018.01.012. Epub 2018 Feb 12. Gynecol Oncol. 2018. PMID: 29395308 Clinical Trial.
Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.
Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S. Polterauer S, et al. Among authors: reinthaller a. Gynecol Oncol. 2019 May;153(2):286-291. doi: 10.1016/j.ygyno.2019.02.007. Epub 2019 Feb 11. Gynecol Oncol. 2019. PMID: 30760408
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: reinthaller a. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: reinthaller a. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Free article. Clinical Trial.
285 results